Search results
Perioperative Chemo Extends Survival in Resectable Esophageal Cancer
MedPage Today· 1 day agoOS rates in the two treatment arms, respectively, were 57.4% and 50.7% at 3 years, and 50.6% and...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 6 hours agoPatients in the trial received 80mg of Tagrisso once daily, along with pemetrexed and a choice of...
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 3 days agoCompared to the chemotherapy control, ivonescimab plus...
Cullinan Therapeutics announces success for zipalertinib as combo therapy
Clinical Trials Arena via Yahoo Finance· 1 day agoEGFR is overexpressed in tumour cells and involved in cell proliferation. Johnson & Johnson’s...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 4 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
ASCO 2024: AbbVie flexes early success of ADC pipeline in solid tumours
Clinical Trials Arena via Yahoo Finance· 1 day agoThe therapy was evaluated as a monotherapy and in combination with AbbVie’s investigative programmed...
Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents
MedPage Today· 3 days agoChina-based trial may present a hurdle to FDA approval, however
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 19 hours agoLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
The Parsons Sun· 4 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
Merck’s KEYTRUDA shows survival benefits in Phase III TNBC trial
Clinical Trials Arena via Yahoo Finance· 6 days agoParticipants were assigned in a 2:1 ratio to receive either KEYTRUDA with chemotherapy or a...